2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-113000
    Cetoleic acid 1002-96-6 99.99%
    Cetoleic acid is a long-chain monounsaturated fatty acid found in deep-sea fish. Cetoleic acid can promote the synthesis of ALA in human HepG2 cells and EPA in vitro in salmon liver cells, affecting cholesterol levels in rodents. Cetoleic acid has potential applications in cardiovascular disease research.
    Cetoleic acid
  • HY-113317
    L-Xylulose 527-50-4 99.80%
    L-Xylulose is an endogenous metabolite present in Blood, Cerebrospinal_Fluid and Urine that can be used for the research of Ribose 5 Phosphate Isomerase Deficiency.
    L-Xylulose
  • HY-114275
    Justicidin B 17951-19-8 99.75%
    Justicidin B is a potent anticancer lignan and proapoptotic agent. Justicidin B is also a bone resorption inhibitor, and has strong antiviral, fungicidal, antiprotozoal effects. Justicidin B significantly inhibits platelet aggregation.
    Justicidin B
  • HY-116442
    Azapropazone 13539-59-8 99.67%
    Azapropazone is an orally active nonsteroidal anti-inflammatory agent. Azapropazone inhibits Xanthine oxidase activity with an IC50 of 70-140 μg/mL. Azapropazone exerts significant cardiomyocyte protective effects on dogs with ischemia-reperfusion injury. Azapropazone reduces arthritis. Azapropazone inhibits Adrenaline-induced platelet aggregation. Azapropazone can be used for the research of myocardial ischemia and reperfusion injury, adjuvant arthritis, and gouty arthritis.
    Azapropazone
  • HY-117200
    Necrostatin-7 351062-08-3 ≥98.0%
    Necrostatin-7 (Nec-7) is a Necroptosis inhibitor with an EC50 of 10.6 μM. Necrostatin-7 inhibits signal transduction from RANK to NFATc1 without affecting the activation of MAPK or NF-κB. Necrostatin-7 suppresses the expression levels of Acp5, Atp6v0d2, Ctsk and Dcstamp. Necrostatin-7 reduces myocardial infarction size, ameliorates adverse left ventricular remodeling, decreases myocardial wall stress, reduces the amount and length of scar tissue, and improves left ventricular function. Necrostatin-7 exerts cardioprotective effects in a rat model of permanent coronary artery occlusion. Necrostatin-7 can be used in research related to osteolytic bone diseases and myocardial infarction.
    Necrostatin-7
  • HY-118941
    BAY 73-1449 693790-96-4 98.40%
    BAY 73-1449 is a selective antagonist of prostacyclin receptor (IP), with high potency (IC50 of less than 0.1 nM) in cAMP assays in Human HEL cells and rat DRG. BAY 73-1449 can be used in the research of lowering blood pressure.
    BAY 73-1449
  • HY-119541
    Ampreloxetine 1227056-84-9 98%
    Ampreloxetine (TD-9855) is a potent and orally active norepinephrine (NE) and serotonin 5-HT inhibitor. Ampreloxetine has the potential for the research of neurogenic orthostatic hypotension.
    Ampreloxetine
  • HY-120644
    BMS-919373 1272353-82-8 98.50%
    BMS-919373 is a selective, potent IKur current blocker. BMS-919373 can be used for the research of cardiovascular diseases.
    BMS-919373
  • HY-120954
    14,15-EE-5(Z)-E 519038-92-7 99.9%
    14,15-EE-5(Z)-E is a structural analogue of 14, 15-epoxide dicartrienoic acid (14,15-EET). 14,15-EE-5(Z)-E antagonizes the relaxation of vascular smooth muscle induced by EET.
    14,15-EE-5(Z)-E
  • HY-121018
    Daltroban 79094-20-5 98.19%
    Daltroban (BM-13505) is a selective and specific thromboxane A2 (TXA2) receptor antagonist. Daltroban increase intracellular calcium in vascular smooth muscle cells. Daltroban shows protective effect in reperfusion injury.
    Daltroban
  • HY-121356
    Carebastine 90729-42-3 ≥99.0%
    Carebastine is an Ebastine (HY-B0674) metabolite and H1-receptor antagonist. Carebastine inhibits VEGFR-2 and Akt phosphorylation. Carebastine exerts an anti-inflammatory effect by inhibiting MIF as well as TNF-α and IL-6 production. Carebastine shows anti-angiogenic activity
    Carebastine
  • HY-121936
    Yohimbic acid 522-87-2 99.86%
    Yohimbic acid is a derivative of Yohimbine Hydrochloride (HY-N0127). Yohimbic acid exhibits vasodilatory and anticancer activities. Yohimbic acid can be used for the research of cancer, inflammation and cardiovascular disease.
    Yohimbic acid
  • HY-122098
    Diaplasinin 481631-45-2 99.87%
    Diaplasinin (PAI-749) is a plasminogen activator inhibitor-1 (PAI-1) inhibitor with IC50 of 295 nM. Diaplasinin has antithrombotic efficacy.
    Diaplasinin
  • HY-123068
    Captopril disulfide 64806-05-9 99.29%
    Captopril disulfide (SQ 14551) is an orally active disulfide dimer prodrug. Captopril disulfide is metabolized to Captopril and acts as a Bradykinin potentiator. Captopril disulfide enhances the vasodilatory effect of Bradykinin in anesthetized rats and the contractile response of isolated guinea pig ileum to Bradykinin. Captopril disulfide exhibits antihypertensive activity in spontaneously hypertensive rats. Captopril disulfide can be used in hypertension-related research.
    Captopril disulfide
  • HY-123348
    Sampatrilat 129981-36-8 99.22%
    Sampatrilat (UK-81252) is a potent and orally active vasopeptidase inhibitor of ACE and neutral endopeptidase (NEP). Sampatrilat inhibits C-domain ACE (Ki=13.8 nM) 12.4-fold more potent than that for the N-domain (Ki=171.9 nM). Sampatrilat (UK-81252) can be used for the study of chronic heart failure and blood pressure regulation.
    Sampatrilat
  • HY-123825
    GX-674 1432913-36-4 98.45%
    GX-674 is a potent, state-dependent, isoform-selective voltage-gated sodium channel 1.7 (Nav1.7) antagonist with an IC50 of 0.1 nM at -40 mV.
    GX-674
  • HY-126426
    CBHcy 88096-02-0 ≥99.0%
    CBHcy is an inhibitor for betaine-homocysteine S-methyltransferase (BGMT), with an IC50 of 0.09 μM. CBHcy upregulates the plasma total homocysteine and causes transient hyperhomocysteinemia in mice model.
    CBHcy
  • HY-126486
    AVE1231 767334-89-4 98.61%
    AVE1231 (A293) is a dual-pore potassium channel TASK-1 inhibitor. AVE1231 blocks carbamoylcholine chloride (HY-B1208)-activated IKACh (IC50=8.4 μM). AVE1231 can be used in the study of arrhythmias and atrial fibrillation.
    AVE1231
  • HY-12765S
    Losartan-d4 (carboxylic acid) 1246820-62-1 98.09%
    Losartan-d4 carboxylic acid (E-3174-d4) is the deuterium labeled Losartan Carboxylic Acid (HY-12765). Losartan Carboxylic Acid (E-3174), an active carboxylic acid metabolite of Losartan, is an angiotensin II receptor type 1 (AT1) antagonist. The Ki values are 0.97, 0.57, 0.67 nM for rat AT1B/AT1A and human AT1, respectively. Losartan Carboxylic Acid blocks the angiotensin II-induced responses in vascular smoothmuscle cells (VSMC). Losartan Carboxylic Acid elevates plasma renin activities and reduces mean arterial pressure.
    Losartan-d4 (carboxylic acid)
  • HY-129496
    NP-313 5397-78-4 99.31%
    NP-313 is a potent antithrombotic agent that inhibits platelet aggregation and activation. NP-313 has dual inhibition of thromboxane A 2 synthesis and selective inhibition of SOCC-mediated Ca2+ inward flow.
    NP-313
Cat. No. Product Name / Synonyms Application Reactivity